EUVIMEDEUVIMED entdecken
Fallbericht

Colony Stimulating Factor‐1 Receptor‐Related Disorder Treated With Ilunazebart

Lukasz Milanowski, Delaney Liskey, Audrey J Strongosky, Jeffrey M Gelfand, Dennis W Dickson iD, Zbigniew K Wszolek iD

Neuropathology · 2026-08 · 46 (4)

DOI: 10.1111/neup.70066 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Neuropathology, online erschienen am 22.06.2026. Verfasst von Lukasz Milanowski und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Mayo Clinic, Jacksonville, Florida, USA. Hauptthemen laut MEDLINE: Receptors, Granulocyte-Macrophage Colony-Stimulating Factor. Die Arbeit nennt 9 Literaturangaben. Gefördert von: Val Shapiro & Jordan Russell Family, Haworth Family Professorship in Neurodegenerative Diseases, NAWA-Polish National Agency for Academic Exchange.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Colony stimulating factor‐1 receptor–related disorder (CSF1R‐RD) is a rare, autosomal dominant neurodegenerative disease caused by loss‐of‐function variants in the CSF1R gene, leading to microglial dysfunction and progressive white matter degeneration. Therapeutic strategies targeting microglial pathways, including activation of triggering receptor expressed on myeloid cells 2 (TREM2), have been proposed to compensate for impaired CSF1R signaling. Iluzanebart (VGL101), a monoclonal antibody TREM2 agonist, has shown promise in preclinical models. We report a longitudinal clinical course, neuroimaging findings, genetic analysis, and postmortem neuropathological examination of a 52‐year‐old patient with genetically confirmed CSF1R‐RD (c.2507G>A, p.Ser836Asn). The patient received iluzanebart as part of a Phase 2 clinical trial. Clinical progression, MRI changes, and histopathological features at autopsy were systematically analyzed. Despite treatment, the patient experienced progressive cognitive decline, neuropsychiatric symptoms, motor impairment, and seizures, culminating in death. Serial neuroimaging demonstrated worsening white matter degeneration and brain atrophy without evidence of therapeutic response. Neuropathological examination revealed characteristic features of CSF1R‐RD, including severe myelin loss, axonal spheroids, infiltration of Iba1‐positive cells with macrophage‐like morphology, and cortical neuronal abnormalities. There was no histological evidence of treatment‐related benefit or harm. This case represents the first clinicopathological assessment of iluzanebart in CSF1R‐RD and demonstrates no observable clinical, radiological, or neuropathological improvement. These findings highlight the challenges of targeting microglial dysfunction in advanced disease and suggest that TREM2 activation alone may be insufficient to alter disease progression.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Receptors, Granulocyte-Macrophage Colony-Stimulating FactorHumansMiddle AgedBrainClinical Trials, Phase II as TopicReceptor, Macrophage Colony-Stimulating Factor

Stichwörter der Autor:innen

CSF1R‐related disorderTREM2iluzanebartleukoencephalopathyneurodegenerative disease

Substanzen

CSF1R protein, humanReceptors, Granulocyte-Macrophage Colony-Stimulating FactorReceptor, Macrophage Colony-Stimulating Factor

Autor:innen und Institutionen

  • Department of Neurology, Mayo Clinic, Jacksonville, Florida, USA.
  • Department of Neurology, Faculty of Health Sciences, Medical University of Warsaw, Warsaw, Poland.
  • Department of Neuroscience, Mayo Clinic, Jacksonville, Florida, USA.
  • Regenerative Sciences Ph.D. Program, Mayo Clinic Graduate School of Biomedical Sciences, Jacksonville, Florida, USA.
  • Weill Institute for Neurosciences, Department of Neurology, University of California, San Francisco, California, USA.

ORCID-Profile: Dennis W Dickson, Zbigniew K Wszolek

Förderung

  • Val Shapiro & Jordan Russell Family
  • Haworth Family Professorship in Neurodegenerative Diseases
  • NAWA-Polish National Agency for Academic Exchange
  • Houlihan Lokey Inc.

Zitieren

APA

Milanowski, L., Liskey, D., Strongosky, A. J., Gelfand, J. M., Dickson, D. W., & Wszolek, Z. K. (2026). Colony Stimulating Factor‐1 Receptor‐Related Disorder Treated With Ilunazebart. Neuropathology, 46(4). https://doi.org/10.1111/neup.70066

Vancouver

Milanowski L, Liskey D, Strongosky AJ, Gelfand JM, Dickson DW, Wszolek ZK. Colony Stimulating Factor‐1 Receptor‐Related Disorder Treated With Ilunazebart. Neuropathology. 2026;46(4). doi:10.1111/neup.70066

BibTeX
@article{Milanowski2026,
  author = {Milanowski, Lukasz and Liskey, Delaney and Strongosky, Audrey J and Gelfand, Jeffrey M and Dickson, Dennis W and Wszolek, Zbigniew K},
  title = {Colony Stimulating Factor‐1 Receptor‐Related Disorder Treated With Ilunazebart},
  journal = {Neuropathology},
  year = {2026},
  volume = {46},
  number = {4},
  doi = {10.1111/neup.70066}
}
Kostenlos starten →